secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZyVersa Therapeutics, Inc. (ZVSA)
CIK:        0001859007
Form:       8-K
Filed at:   2026-07-10T20:30:31+00:00
Accession:  0001493152-26-032851
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 5.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

ZyVersa Therapeutics explores cost cuts, potential going dark, and asset sales; director Park resigns
--------------------------------------------------------------------------------

- Director Min Chul Park resigned effective July 8, 2026, for personal reasons, no disagreement with company.
- CEO Stephen Glover and CFO Peter Wolfe voluntarily accepted reduced compensation to preserve cash.
- Company considering divesting VAR 200 or IC 100 product candidates and reducing headcount.
- Company may go dark by suspending SEC reporting obligations under Rule 12h-3.
- Also evaluating sale of company or assets, restructuring, or reorganization to maximize shareholder value.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1859007/000149315226032851/0001493152-26-032851-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1859007/000149315226032851/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-032851

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer